In short: does semaglutide cause hair loss?<\/p>\n
Yes, semaglutide can trigger hair loss, but almost always only indirectly. The culprit is not the drug itself, it is the rapid weight loss, which sets off a telogen effluvium: a temporary, diffuse shedding. This usually resolves on its own once your weight stabilises, so hair loss alone is rarely a reason to stop treatment.<\/p>\n
- \n
- Cause:<\/strong> the rapid weight loss, not a toxic effect of the drug on the hair root. In the Wegovy trials (2.4 mg) around 3% of patients were affected, compared with 1% on placebo.<\/li>\n
- Temporary and reversible:<\/strong> once your weight stabilises, the hair typically grows back within 6 to 12 months.<\/li>\n
- Risk depends on how fast you lose weight:<\/strong> losing more than 20% of your body weight nearly doubles the risk. That is why Ozempic (lower dose) affects fewer people than Wegovy.<\/li>\n
- When to see a doctor:<\/strong> with bald patches, no regrowth after 12 months, or a patterned loss alongside a family history (suggesting hereditary hair loss).<\/li>\n<\/ul>\n<\/div>\n\n\n\n
If you are losing hair on semaglutide, that is in most cases no reason to stop treatment. What matters more is reading the cause correctly and knowing the handful of levers you can pull to lessen the loss. That is exactly what we will work through, step by step.<\/p>\n\n\n\n
Does semaglutide cause hair loss? The clinical evidence<\/h2>\n\n\n\n
![\"Bar](\"https:\/\/elithair.com\/uk\/wp-content\/uploads\/sites\/3\/2026\/06\/stats_semaglutid_uk.webp\")
Alopecia incidence on semaglutide rises with weight loss: 1% on placebo, 3% on Wegovy 2.4 mg, and 5.3% in patients losing more than 20% of body weight.<\/figcaption><\/figure>\n\n\n\n The most reliable source is the official prescribing information from the regulators. And here the most important quirk of this drug shows up immediately: semaglutide is sold in three very different products, and only one of them lists hair loss in its label at all.<\/p>\n\n\n\n
- \n
- Wegovy (semaglutide 2.4 mg, weekly, for obesity):<\/strong> alopecia is listed in section 6.1 of the FDA prescribing information as a known side effect. Incidence is 3% in adults (2.4 mg) versus 1% on placebo. In adolescents aged 12 and over it reaches 4% versus 0%. The FDA explicitly notes that the hair loss was associated with weight reduction.<\/li>\n
- Ozempic (semaglutide 0.5 to 2.0 mg, weekly, for type 2 diabetes):<\/strong> hair loss is NOT listed in section 6.1 of the FDA label, at most as a post-marketing report with no frequency given. The reason lies in the much smaller weight loss seen in the diabetes indication.<\/li>\n
- Rybelsus (semaglutide 7 to 14 mg, oral, daily, for type 2 diabetes):<\/strong> again, no hair loss in the label. In the PIONEER trial programme the weight loss was around 4 kg, too little to trigger a telogen effluvium.<\/li>\n<\/ul>\n\n\n\n
In Europe, the Wegovy prescribing information classes alopecia as “common”, that is affecting at least 1 in 100 patients treated, with a rate of 2.5% versus 1.0% on placebo. The important addition in the SmPC: the events were mostly mild, and most patients recovered while still on treatment.<\/p>\n\n\n\n
What the STEP trials show<\/h3>\n\n\n\n
The licensing of semaglutide for weight loss rests on the STEP trial programme. In STEP 1 (Wilding et al., NEJM 2021, n=1,961, 68 weeks) the mean weight loss was −14.9%, and alopecia occurred in around 3% versus 0.9% on placebo. STEP 5, run over 104 weeks, confirmed the picture with −15.2% weight loss and roughly 3.2% alopecia. One detail within these data is decisive: patients who lost more than 20% of their body weight showed an alopecia rate of 5.3%, against only 2.5% in those who lost less than 20%. It is the extent of the weight loss that drives the risk, not the substance itself.<\/p>\n\n\n\n
FAERS pharmacovigilance and real-world data<\/h3>\n\n\n\n
There are signals outside the licensing trials too. An analysis of the FDA’s adverse-event database FAERS, the system in which doctors and patients report suspected side effects, found a reporting odds ratio of 2.46 for semaglutide (Godfrey et al., JEADV 2025) (95% CI: 2.14 to 2.83). The reporting odds ratio shows how much more often a side effect is reported for a drug than for others, so a value above 1 is a warning sign. This is the first solid pharmacovigilance signal for the weekly GLP-1 receptor agonists. A large real-world cohort study using the TriNetX database (n=547,993 matched patients) found an increased risk of non-scarring alopecia at 12 months, with an adjusted odds ratio of 1.40. In a meta-analysis of 24 studies (Gupta et al., Science Progress 2026, more than 84,000 patients), the alopecia risk on GLP-1 therapies was roughly 3.4 times higher than on placebo.<\/p>\n\n\n\n
\nWorth keeping in perspective: all of these observational studies carry a high risk of bias, and prospective trials with a dermatological diagnosis as their primary endpoint are still lacking. A direct causal link between the drug itself and hair loss, independent of the weight loss, has not been definitively proven.\n<\/div>\n\n\n\nHow does the hair loss on semaglutide show up?<\/h2>\n\n\n\n
The typical hair loss on semaglutide is a diffuse, even thinning across the whole scalp. There are no clearly defined bald patches. In practice, most people simply notice far more hair in the brush, in the shower drain and on the pillow. Instead of the normal 50 to 100 hairs a day, 150 or more come out for a while. When you put your hair up it feels thinner, and the parting looks wider than before. This pattern is exactly what is typical of a telogen effluvium and sets it apart from a patterned diffuse hair loss<\/a> with a clear progression.<\/p>\n\n\n\n
![\"Comparison](\"https:\/\/elithair.com\/uk\/wp-content\/uploads\/sites\/3\/2026\/06\/te_vs_aga_uk.webp\")
Diffuse telogen effluvium (left) versus patterned hereditary hair loss, AGA (right).<\/figcaption><\/figure>\n\n\n\n This needs to be distinguished from androgenetic alopecia (AGA), the hereditary, hormone-driven hair loss with its characteristic pattern. In men it shows up at the temples and on the crown following the Hamilton-Norwood pattern, in women as thinning along the parting in the so-called Christmas-tree pattern. Interestingly, in a cohort of 283 GLP-1 users (Burke et al., JAAD 2025) it was not telogen effluvium but AGA that was the most commonly diagnosed subtype, in 19 of 35 cases. That suggests semaglutide unmasks an AGA in some people that was already present but until then invisible. We explain more about this mechanism in our article on androgenetic alopecia<\/a>.<\/p>\n\n\n\n
In very rare individual cases, alopecia areata has also been described, that is round, well-defined bald patches of autoimmune origin. A causal link with semaglutide has not been proven, but if you notice patchy loss you should see a dermatologist promptly.<\/p>\n\n\n\n
Why does it happen? How semaglutide works<\/h2>\n\n\n\n
To understand the hair loss properly, you need to know what semaglutide actually does in the body. Semaglutide is a glucagon-like peptide-1 receptor agonist, GLP-1 RA for short. It mimics the body’s own gut hormone GLP-1 and activates its receptors in the pancreas, the brain and other organs. The result: insulin release is increased in a glucose-dependent way, gastric emptying is slowed, and, above all, appetite is dampened in the hypothalamus. You eat less, you feel full for longer, and your weight comes down. On Wegovy 2.4 mg the average loss is −14.9% over 68 weeks, and in some patients as much as 25%.<\/p>\n\n\n\n
And it is precisely this rapid weight loss that is the real trigger for the hair loss, not the drug directly. The body reads a fast, marked drop in weight as physiological stress. It prioritises vital organs and diverts energy and nutrients away from functions that are not essential for survival, and hair growth is one of those. The result is a telogen effluvium.<\/p>\n\n\n\n
![\"Diagram](\"https:\/\/elithair.com\/uk\/wp-content\/uploads\/sites\/3\/2026\/06\/mechanism_uk.webp\")
How semaglutide triggers a telogen effluvium through rapid weight loss, without directly damaging the follicle.<\/figcaption><\/figure>\n\n\n\n In detail it works like this. Normally 90 to 95% of your scalp follicles are in the active growth phase (anagen) and only 5 to 10% in the resting phase (telogen). Under severe stress the body can push up to 70% of the anagen hairs into the telogen phase prematurely, all at once. The HPA axis (the hormonal stress axis between the brain and the adrenal glands) plays a central role here: raised cortisol and corticotropin-releasing hormone (CRH) drive the follicles into rest. A characteristic delay of around 2 to 3 months sits between the trigger and the visible shedding, because the hairs sent into telogen only fall out at the end of their resting phase. Once you understand this hair growth cycle<\/a>, it becomes obvious why the loss only appears months after starting treatment.<\/p>\n\n\n\n
Nutrient deficiencies as an amplifier<\/h3>\n\n\n\n
Because you eat less on semaglutide, deficiencies can develop that make the telogen effluvium worse. Three are particularly relevant:<\/p>\n\n\n\n
- \n
- Protein:<\/strong> hair is roughly 90% made up of the structural protein keratin. A protein intake below 0.8 g\/kg\/day is associated with a doubling of the TE risk, and when your appetite is suppressed it is all too easy to fall short.<\/li>\n
- Iron and ferritin:<\/strong> iron is a cofactor of ribonucleotide reductase, the rate-limiting enzyme of DNA synthesis in the fast-growing hair matrix cells. In a controlled study, the mean ferritin level in patients with TE was 24.3 ng\/mL versus 45.6 ng\/mL in healthy controls.<\/li>\n
- Zinc:<\/strong> essential for protein synthesis in the follicle. In chronic TE, significantly lower zinc levels have been measured (49.9 versus 60.5 \u00b5g\/dL).<\/li>\n<\/ul>\n\n\n\n
For vitamin D the data are contradictory. The vitamin D receptor regulates the hair cycle, but not every study finds lower levels in TE patients. We therefore do not present a vitamin D deficiency as a confirmed cause.<\/p>\n\n\n\n
No direct follicle-toxic effect of the drug<\/h3>\n\n\n\n
This is the key distinction, and it is reassuring: all the current review articles agree that a direct cytotoxic effect of semaglutide on the hair follicles has not been proven. GLP-1 receptors have indeed been detected in the hair follicles of mice, but solid evidence of functional GLP-1 receptors in human hair follicles is still awaited. Put another way: semaglutide does not poison your hair. Through the weight loss it triggers a temporary stress reaction. From this follows an important practical consequence. Hair loss alone is usually no reason to stop treatment, because the medical benefit in obesity and type 2 diabetes outweighs it.<\/p>\n\n\n\n
\nHow it unfolds, step by step:<\/p>\n
- \n
- \u278a Semaglutide dampens appetite, you lose a lot of weight (on average −15%, sometimes up to −25%).<\/li>\n
- \u278b The rapid weight loss means physiological stress plus a calorie deficit.<\/li>\n
- \u278c Nutrient deficiencies develop: protein, ferritin and zinc all drop.<\/li>\n
- \u278d Cortisol and CRH rise, and up to 70% of the follicles enter the resting phase.<\/li>\n
- \u278e After a latency of 2 to 3 months, diffuse hair loss appears.<\/li>\n
- \u278f Reversible after 6 to 12 months. No direct follicle damage from the drug.<\/li>\n<\/ul>\n<\/div>\n\n\n\n
Timeline: when does the hair loss start, and when does it stop?<\/h2>\n\n\n\n
The dose escalation of semaglutide is closely tied to the hair-loss timeline. Wegovy is titrated up over 16 weeks: 0.25 mg, then 0.5 mg, 1.0 mg, 1.7 mg and finally 2.4 mg, in 4-week steps. With each dose increase the weight loss speeds up. That is why the shedding phase, the period of markedly increased loss of the hairs previously sent into rest, often begins after the first significant dose increase. Ozempic escalates more slowly and only up to a maximum of 2.0 mg, which goes some way to explaining its smaller weight loss and the absence of a label signal.<\/p>\n\n\n\n
![\"Timeline](\"https:\/\/elithair.com\/uk\/wp-content\/uploads\/sites\/3\/2026\/06\/timeline_uk.webp\")
Typical timeline of telogen effluvium on semaglutide, from latency to cosmetic recovery.<\/figcaption><\/figure>\n\n\n\n \n
- Iron and ferritin:<\/strong> iron is a cofactor of ribonucleotide reductase, the rate-limiting enzyme of DNA synthesis in the fast-growing hair matrix cells. In a controlled study, the mean ferritin level in patients with TE was 24.3 ng\/mL versus 45.6 ng\/mL in healthy controls.<\/li>\n
- Ozempic (semaglutide 0.5 to 2.0 mg, weekly, for type 2 diabetes):<\/strong> hair loss is NOT listed in section 6.1 of the FDA label, at most as a post-marketing report with no frequency given. The reason lies in the much smaller weight loss seen in the diabetes indication.<\/li>\n
- Temporary and reversible:<\/strong> once your weight stabilises, the hair typically grows back within 6 to 12 months.<\/li>\n